EMR

Business Context and Reporting Period

Company: Emerson Electric Co.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and nine months ended June 30, 2024 (Fiscal Q3 2024)
Key Context: The period is significantly impacted by the October 2023 acquisition of National Instruments (NI), now reported as the "Test & Measurement" segment, and the June 2024 agreement to sell Emerson's remaining 40% equity interest and note receivable in Copeland (formerly Climate Technologies).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 11% in Q3 and 16% YTD, driven primarily by the NI acquisition (adding ~9% in Q3 and ~10% YTD) and underlying organic growth of 3% in Q3 and 7% YTD.
• Profitability Decline (GAAP): Earnings from continuing operations dropped 46% in Q3 and 30% YTD. This is largely due to a one-time $279 million pretax loss recorded in Q3 to adjust the carrying value of the Copeland note receivable to reflect its sale price.
• Adjusted Performance: Excluding one-time items, Adjusted Diluted EPS from continuing operations increased 11% in Q3 and 27% YTD, reflecting strong operational leverage and the contribution of the NI acquisition.
• Balance Sheet: Cash and equivalents decreased significantly from $8.05 billion (Sep 30, 2023) to $2.30 billion (June 30, 2024) due to the $8.34 billion cash outflow for the NI acquisition. Short-term borrowings increased to $2.99 billion to fund the acquisition.
• Discontinued Operations: Q3 2023 included an $8.7 billion gain from the sale of Climate Technologies. Q3 2024 discontinued operations reflect a small loss of $15 million related to equity method losses on the retained Copeland interest.

Guidance, Outlook, and Risks

Fiscal 2024 Outlook

• Net Sales: Expected to be up approximately 15% for the full year, with underlying sales up ~6% (excluding ~9.5% from NI and -0.5% FX impact).
• EPS (Continuing Ops): Expected to be $2.82 to $2.87.
• Adjusted EPS (Continuing Ops): Expected to be $5.45 to $5.50.
• Cash Flow: Operating cash flow expected at ~$3.2 billion; Free cash flow expected at ~$2.8 billion.
• Capital Return: Approximately $300 million in share repurchases and $1.2 billion in dividends expected for the fiscal year.

Management Commentary & Risks

• Copeland Transaction: Emerson entered definitive agreements to sell its 40% equity interest in Copeland for $1.5 billion and the note receivable for $1.9 billion. The note sale closed August 2, 2024; the equity sale is expected to close by end of August 2024. Proceeds (~$2.9 billion after-tax) will be used to pay down debt.
• NI Integration: The acquisition has increased intangible amortization ($419 million YTD) and restructuring costs ($170 million YTD), impacting GAAP margins but contributing to Adjusted EBITA growth.
• Risks: Global conflicts (Russia-Ukraine), economic conditions, currency fluctuations, supply chain constraints, and cybersecurity threats.

Investor Verification Checklist

• Copeland Sale Closure: Verify the final closing of the 40% equity interest sale in Copeland and the exact timing of cash receipt.
• Debt Reduction: Monitor the deployment of the ~$2.9 billion Copeland proceeds to reduce the elevated short-term debt levels incurred for the NI acquisition.
• NI Integration Costs: Track the run-rate of intangible amortization and restructuring costs associated with the National Instruments acquisition to assess long-term margin normalization.
• Underlying Growth: Distinguish between organic growth (volume/price) and acquisition-driven growth in future quarters to evaluate core business health.
• China Exposure: Review segment-specific data for China, which showed declines in both Intelligent Devices and Software & Control segments in Q3.